Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Delcath Systems, Inc.

LOS ANGELES--(BUSINESS WIRE)--

Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of a class (the “Class”) comprising all purchasers of the securities of Delcath Systems, Inc. (“Delcath” or the “Company”) (DCTH) between April 21, 2010 and May 2, 2013, inclusive (the “Class Period”).

A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE CONTACT US TOLL-FREE AT (888) 773-9224, AT (212) 682-5340 OR AT SHAREHOLDERS@GLANCYLAW.COM. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.

Delcath operates as a specialty pharmaceutical and medical device company focusing on the field of oncology, primarily the development of CHEMOSAT/Melblez Kit system, which administers concentrated regional chemotherapy to the liver. The Complaint alleges that throughout the Class Period defendants misrepresented or failed to disclose material adverse facts about, among other things, the Company's New Drug Application seeking Food and Drug Administration (FDA) approval for commercial sale of Melblez Kit -- Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System -- for the treatment of patients with unresectable ocular melanoma metastatic to the liver, including substantial and severe toxicity, and deaths associated with the drug’s adverse reactions.

On May 2, 2013 the Company disclosed that the FDA’s Oncologic Drugs Advisory Committee voted 16-0, with no abstentions, that Melblez Kit’s treatment benefits do not outweigh the risks associated with the procedure. The next day, as a result of this news, the price of Delcath shares dropped more than 40% on extremely heavy trading volume.

If you are a member of the Class described above and meet certain legal requirements, you may move the Court no later than July 8, 2013 to serve as lead plaintiff. To learn more, or if you purchased Delcath stock prior to the Class Period, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.